Unraveling kinase signaling pathways with chemical genetic and chemical proteomic approaches

Cell Cycle

Volumn 4, Issue 3, 2005, Pages 434-437

  Beillard, Emmanuel ^a   Witte, Owen N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bcr Abl; Chemical genetics; Chemical proteomics; Downstream target; Inhibitor sensitive allele; Kinase inhibitor specificity; Kinase substrate; Phosphorylation; Signaling pathway

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ABELSON KINASE; ADENOSINE TRIPHOSPHATE DERIVATIVE; BCR ABL PROTEIN; BENZYL DERIVATIVE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GENE PRODUCT; IMATINIB; LIGAND; PHA 539136; PHOSPHORUS 32; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PP 58; PROTEIN KINASE; PROTEIN SERINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PURVALANOL; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; STEM CELL FACTOR; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ALLELE; BACTERIOPHAGE; BINDING SITE; BIOLOGICAL ACTIVITY; CARCINOGENICITY; CATALYSIS; CHEMICAL GENETICS; DESENSITIZATION; DNA MODIFICATION; ENZYME SPECIFICITY; ENZYME SYNTHESIS; GENE MUTATION; GENETIC ENGINEERING; HUMAN; ISOTOPE LABELING; LEUKEMIA CELL; MASS SPECTROMETRY; MYELOPROLIFERATIVE DISORDER; ONCOGENE; PATHOLOGY; PHOSPHORYLATION; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN IMMOBILIZATION; PROTEIN MODIFICATION; PROTEOMICS; REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION;

EID: 25444501580     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.3.1557     Document Type: Review

References (45)

1. Caenepeel S, Charydczak G, Sudarsanam S, Hunter T, Manning G. The mouse kinome: Discovery and comparative genomics of all mouse protein kinases. Proc Natl Acad Sci USA 2004; 101:11707-12.
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298:1912-34.
3. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410:37-40.
4. Hunter T. Signaling - 2000 and beyond. Cell 2000; 100:113-27.
5. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1:309-15.
6. Alaimo PJ, Shogren-Knaak MA, Shokat KM. Chemical genetic approaches for the elucidation of signaling pathways. Curr Opin Chem Biol 2001; 5:360-7.
7. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351:95-105.
8. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: An update. Biochem J 2003; 371:199-204.
9. Wong S, Witte ON. The BCR-ABL story: Bench to bedside and back. Annu Rev Immunol 2004; 22:247-306.
10. Stockwell BR. Chemical genetics: Ligand-based discovery of gene function. Nat Rev Genet 2000; 1:116-25.
11. Bishop AC, Buzko O, Shokat KM. Magic bullets for protein kinases. Trends Cell Biol 2001; 11:167-72.
12. Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci USA 2004; 25:25.
13. Shah K, Liu Y, Deirmengian C, Shokat KM. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc Natl Acad Sci USA 1997; 94:3565-70.
14. Bishop A, Buzko O, Heyeck-Dumas S, Jung I, Kraybill B, Liu Y, Shah K, Ulrich S, Witucki L, Yang F, Zhang C, Shokat KM. Unnatural ligands for engineered proteins: New tools for chemical genetics. Annu Rev Biophys Biomol Struct 2000; 29:577-606.
15. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, Shimizu E, Tsien JZ, Schultz PG, Rose MD, Wood JL, Morgan DO, Shokat KM. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 2000; 407:395-401.
16. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and Fynt-dependent T cell activation. J Biol Chem 1996; 271:695-701.
17. Waltenberger J, Uecker A, Kroll J, Frank H, Mayr U, Bjorge JD, Fujita D, Gazit A, Hombach V, Levitzki A, Bohmer FD. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. Circ Res 1999; 85:12-22.
18. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112:831-43.
19. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-80.
20. von Bubnoff N, Veach DR, Miller WT, Li W, Sanger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res 2003; 63:6395-404.
21. Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, Horvath Z, Keri G, Ullrich A, Daub H. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 2004; 11:691-701.
22. Liu Y, Shah K, Yang F, Witucki L, Shokat KM. A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorg Med Chem 1998; 6:1219-26.
23. Ulrich SM, Kenski DM, Shokat KM. Engineering a "methionine clamp" into Src family kinases enhances specificity toward unnatural ATP analogues. Biochemistry 2003; 42:7915-21.
24. Chaudhary A, Brugge JS, Cooper JA. Direct phosphorylation of focal adhesion kinase by c-Src: Evidence using a modified nucleotide pocket kinase and ATP analog. Biochem Biophys Res Commun 2002; 294:293-300.
25. Ubersax JA, Woodbury EL, Quang PN, Paraz M, Blethrow JD, Shah K, Shokat KM, Morgan DO. Targets of the cyclin-dependent kinase Cdk1. Nature 2003; 425:859-64.
26. Eblen ST, Kumar NV, Shah K, Henderson MJ, Watts CK, Shokat KM, Weber MJ. Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs. J Biol Chem 2003; 278:14926-35.
27. Shah K, Shokat KM. A chemical genetic screen for direct v-Src substrates reveals ordered assembly of a retrograde signaling pathway. Chem Biol 2002; 9:35-47.
28. Liu Y, Witucki LA, Shah K, Bishop AC, Shokat KM. Src-Abl tyrosine kinase chimeras: Replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities. Biochemistry 2000; 39:14400-8.
29. Sun T, Campbell M, Gordon W, Arlinghaus RB. Preparation and application of antibodies to phosphoamino acid sequences. Biopolymers 2001; 60:61-75.
30. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004; 5:33-44.
31. Ting AY, Witte K, Shah K, Kraybill B, Shokat KM, Schultz PG. Phage-display evolution of tyrosine kinases with altered nucleotide specificity. Biopolymers 2001; 60:220-8.
32. Maly DJ, Allen JA, Shokat KM. A mechanism-based cross-linker for the identification of kinase-substrate pairs. J Am Chem Soc 2004; 126:9160-1.
33. Godl K, Daub H. Proteomic analysis of kinase inhibitor selectivity and function. Cell Cycle 2004; 3:393-5.
34. Daub H, Godl K, Brehmer D, Klebl B, Muller G. Evaluation of kinase inhibitor selectivity by chemical proteomics. Assay Drug Dev Technol 2004; 2:215-24.
35. Knockaert M, Meijer L. Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. Biochem Pharmacol 2002; 64:819-25.
36. Brehmer D, Godl K, Zech B, Wissing J, Daub H. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol Cell Proteomics 2004; 3:490-500.
37. Lolli G, Thaler F, Valsasina B, Roletto F, Knapp S, Uggeri M, Bachi A, Matafora V, Storici P, Stewart A, Kalisz HM, Isacchi A. Inhibitor affinity chromatography: Profiling the specific reactivity of the proteome with immobilized molecules. Proteomics 2003; 3:1287-98.
38. Wissing J, Godl K, Brehmer D, Blencke S, Weber M, Habenberger P, Stein-Gerlach M, Missio A, Cotten M, Muller S, Daub H. Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. Mol Cell Proteomics 2004; 8:8.
39. Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, Grant K, Fergusson D, Mottram J, Soete M, Dubremetz JF, Le Roch K, Doerig C, Schultz P, Meijer L. Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised inhibitors. Chem Biol 2000; 7:411-22.
40. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 2003; 100:15434-9.
41. Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J, Clarkson B. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002; 62:4244-55.
42. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36:453-61.
43. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 2002; 32:201-5.
44. Kapoor TM, Mitchison TJ. Allele-specific activators and inhibitors for kinesin. Proc Natl Acad Sci USA 1999; 96:9106-11.
45. Lin Q, Jiang F, Schultz PG, Gray NS. Design of allele-specific protein methyltransferase inhibitors. J Am Chem Soc 2001; 123:11608-13.